These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 20383751)

  • 1. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors.
    Mitrus I; Sochanik A; Cichoń T; Szala S
    Acta Biochim Pol; 2009; 56(1):161-5. PubMed ID: 19287800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
    Herringson TP; Altin JG
    J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
    Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
    Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.
    Seynhaeve AL; Hoving S; Schipper D; Vermeulen CE; de Wiel-Ambagtsheer Ga; van Tiel ST; Eggermont AM; Ten Hagen TL
    Cancer Res; 2007 Oct; 67(19):9455-62. PubMed ID: 17909055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
    Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
    Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
    Eliaz RE; Szoka FC
    Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
    Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
    J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
    Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
    J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
    Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
    J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.